Short Interest in GeoVax Labs Inc. (NASDAQ:GOVX) Rises By 218.4%

GeoVax Labs Inc. (NASDAQ:GOVX) saw a large growth in short interest in August. As of August 14th, there was short interest totaling 182,364 shares, a growth of 218.4% from the July 30th total of 57,276 shares. Based on an average daily volume of 200,659 shares, the short-interest ratio is currently 0.9 days. Approximately 5.3% of the company’s shares are short sold.

Hedge Funds Weigh In On GeoVax Labs

A number of institutional investors have recently bought and sold shares of the stock. Ieq Capital LLC bought a new stake in GeoVax Labs during the 2nd quarter valued at approximately $1,352,000. NFJ Investment Group LLC purchased a new position in shares of GeoVax Labs during the 2nd quarter worth approximately $1,419,000. Rice Hall James & Associates LLC bought a new position in shares of GeoVax Labs in the 2nd quarter worth approximately $1,888,000. Man Group plc bought a new position in shares of GeoVax Labs in the 2nd quarter worth approximately $2,396,000. Finally, Jane Street Group LLC purchased a new position in shares of GeoVax Labs in the 1st quarter valued at approximately $27,000. 6.09% of the stock is owned by institutional investors.

GeoVax Labs Price Performance

GeoVax Labs stock traded up $0.08 during mid-day trading on Thursday, reaching $0.71. 3,415,079 shares of the company traded hands, compared to its average volume of 2,158,241. GeoVax Labs has a 52-week low of $0.59 and a 52-week high of $19.20. The firm has a market capitalization of $2.46 million, a price-to-earnings ratio of -0.06 and a beta of 3.73. The firm’s 50 day moving average price is $0.94 and its 200 day moving average price is $1.40.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Monday, July 27th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($2.16) by $1.19. On average, sell-side analysts anticipate that GeoVax Labs will post -4.94 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, GeoVax Labs currently has an average rating of “Reduce” and an average price target of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.